GBLX - GB Sciences Stock Price, News & Analysis

$0.24 -0.02 (-7.69 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$0.25
Today's Range$0.24 - $0.26
52-Week Range$0.21 - $0.56
Volume583,568 shs
Average Volume293,601 shs
Market Capitalization$30.79 million
P/E RatioN/A
Dividend YieldN/A
Beta0.97

About GB Sciences (OTCMKTS:GBLX)

GB Sciences logoGB Sciences, Inc., formerly Growblox Sciences, Inc., is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments. It intends to conduct its business operations, through its subsidiaries in approximately three operating units, which include Solutions, Sciences and Product divisions. The Solutions division involves the development and use of its suite of controlled-climate indoor agricultural technology growing and cultivation Suites, including TissueBLOX, GrowBLOX, CureBLOX and ExtractionLAB. The Science division is engaged in preclinical testing of its biopharmaceutical cannabinoid product prototypes to begin future human clinical trials.


Industry, Sector and Symbol

Industry N/A
Sub-IndustryCannabis
SectorN/A
SymbolOTCMKTS:GBLX
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($0.12)
Net IncomeN/A
Net Margins-5,761.07%
Return on Equity-158.06%
Return on Assets-100.57%

Miscellaneous

EmployeesN/A
Outstanding Shares127,750,000

Frequently Asked Questions for GB Sciences (OTCMKTS:GBLX)

What is GB Sciences' stock symbol?

GB Sciences trades on the OTCMKTS under the ticker symbol "GBLX."

How were GB Sciences' earnings last quarter?

GB Sciences, Inc. (OTCMKTS:GBLX) announced its quarterly earnings results on Monday, November, 14th. The company reported ($0.04) EPS for the quarter. GB Sciences had a negative net margin of 5,761.07% and a negative return on equity of 158.06%. View GB Sciences' Earnings History.

Who are some of GB Sciences' key competitors?

Who are GB Sciences' key executives?

GB Sciences' management team includes the folowing people:

  • John Poss, Chairman of the Board, President, Chief Executive Officer (Age 69)
  • Leslie Bocskor, Independent Vice Chairman of the Board (Age 52)
  • Ksenia Griswold, Chief Financial Officer, Vice President (Age 34)
  • Krin Ellery Kuethe, Chief Operating Officer (Age 32)
  • Andrea Small-Howard Ph.D., Chief Science Officer, Director (Age 48)
  • Shane Terry, Independent Director (Age 38)

How do I buy GB Sciences stock?

Shares of GB Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GB Sciences' stock price today?

One share of GB Sciences stock can currently be purchased for approximately $0.24.

How big of a company is GB Sciences?

GB Sciences has a market capitalization of $30.79 million.

How can I contact GB Sciences?

GB Sciences' mailing address is 6450 Cameron St Ste 110A, LAS VEGAS, NV 89118-4337, United States. The company can be reached via phone at +1-888-8953594.


MarketBeat Community Rating for GB Sciences (GBLX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  38
MarketBeat's community ratings are surveys of what our community members think about GB Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for GB Sciences (OTCMKTS:GBLX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for GB Sciences (OTCMKTS:GBLX)

Price Target History for GB Sciences (OTCMKTS:GBLX)

Analysts' Ratings History for GB Sciences (OTCMKTS:GBLX)

Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History and Estimates Chart for GB Sciences (OTCMKTS:GBLX)

Earnings by Quarter for GB Sciences (OTCMKTS:GBLX)

Earnings History by Quarter for GB Sciences (OTCMKTS GBLX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016Q2 2017($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GB Sciences (OTCMKTS:GBLX)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for GB Sciences (OTCMKTS:GBLX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for GB Sciences (OTCMKTS GBLX)

Insider Trades by Quarter for GB Sciences (OTCMKTS:GBLX)

Insider Trades by Quarter for GB Sciences (OTCMKTS GBLX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/4/2017Craig EllinsInsiderSell100,000$0.26$26,000.00View SEC Filing  
10/6/2016Lazarus Management Co LlcMajor ShareholderSell785,000$0.31$243,350.00View SEC Filing  
10/8/2014Lazarus Management Co LlcMajor ShareholderBuy77,700$0.69$53,613.00View SEC Filing  
10/2/2014Lazarus Management Co LlcMajor ShareholderBuy39,605$0.85$33,664.25View SEC Filing  
9/29/2014Lazarus Management Co LlcMajor ShareholderBuy64,000$0.90$57,600.00View SEC Filing  
9/17/2014Lazarus Management Co LlcMajor ShareholderBuy47,640$0.76$36,206.40View SEC Filing  
8/27/2014Israel Opportunities F LazarusMajor ShareholderBuy46,625$1.05$48,956.25View SEC Filing  
8/1/2014Israel Opportunities F LazarusMajor ShareholderBuy39,800$1.24$49,352.00View SEC Filing  
7/30/2014Israel Opportunities F LazarusMajor ShareholderBuy87,077$1.24$107,975.48View SEC Filing  
7/2/2014Lazarus Investment Partners LlMajor ShareholderBuy269,632$1.19$320,862.08View SEC Filing  
6/2/2014Lazarus Management Co LlcMajor ShareholderBuy1,000,000$0.50$500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for GB Sciences (OTCMKTS GBLX)

Source:
DateHeadline
GB Sciences Exceeds Its Gross Revenue Projections for October, Doubles the Industry Average Yield Per Active Flower LightGB Sciences Exceeds Its Gross Revenue Projections for October, Doubles the Industry Average Yield Per Active Flower Light
finance.yahoo.com - November 15 at 5:36 AM
GB Sciences is HappyGB Sciences is Happy
finance.yahoo.com - November 13 at 9:50 AM
The Scientific Advisory Board will oversee the development of GB Sciences’ Cannabis-Based Therapies and Clinical TrialsThe Scientific Advisory Board will oversee the development of GB Sciences’ Cannabis-Based Therapies and Clinical Trials
globenewswire.com - November 1 at 8:09 PM
GB Sciences, Inc. Partners With Cura Cannabis Solutions And Enters The Lucrative Cannabis Oil Market In NevadaGB Sciences, Inc. Partners With Cura Cannabis Solutions And Enters The Lucrative Cannabis Oil Market In Nevada
finance.yahoo.com - October 30 at 7:47 PM
GB Sciences Receives The Prestigious Spirit Of The Law AwardGB Sciences Receives The Prestigious 'Spirit Of The Law' Award
finance.yahoo.com - October 26 at 7:31 AM
GB Sciences Increased Sales 400% Since First HarvestGB Sciences Increased Sales 400% Since First Harvest
finance.yahoo.com - October 23 at 6:41 PM
GB Sciences Obtains Exclusive Worldwide License on a Time-Released Cannabinoid Formulation for Neuropathic PainGB Sciences Obtains Exclusive Worldwide License on a Time-Released Cannabinoid Formulation for Neuropathic Pain
finance.yahoo.com - October 17 at 7:37 PM
Marijuana and Cannabis Business Becoming One of the Markets Fastest Grow IndustriesMarijuana and Cannabis Business Becoming One of the Market's Fastest Grow Industries
www.nasdaq.com - October 10 at 4:39 PM
Nanotechnology Research Collaboration with Universidad de Sevilla to Create Time-Released Formulation for GB Sciences THC-Free Chronic Pain TherapyNanotechnology Research Collaboration with Universidad de Sevilla to Create Time-Released Formulation for GB Sciences' THC-Free Chronic Pain Therapy
finance.yahoo.com - October 10 at 4:39 PM
Innovative Partnership Forged Between LSU AgCenter And GB Sciences To Advance The Understanding Of The Cannabis PlantInnovative Partnership Forged Between LSU AgCenter And GB Sciences To Advance The Understanding Of The Cannabis Plant
finance.yahoo.com - September 18 at 6:30 PM
Groundbreaking Collaboration Between A Major University And A Medical Cannabis CompanyGroundbreaking Collaboration Between A Major University And A Medical Cannabis Company
finance.yahoo.com - September 18 at 6:30 PM
GB Sciences Inc (GBLX) Insider Sells $26,000.00 in StockGB Sciences Inc (GBLX) Insider Sells $26,000.00 in Stock
www.americanbankingnews.com - August 7 at 8:02 PM
GB Sciences Joins With Los Coyotes Band Of Cahuilla And Cupeno Indians As It Enters The Gigantic California Cannabis MarketGB Sciences Joins With Los Coyotes Band Of Cahuilla And Cupeno Indians As It Enters The Gigantic California Cannabis Market
finance.yahoo.com - August 2 at 7:49 PM
GB Sciences initiates cannabis-based therapy clinical trials consulting services agreement with Worldwide Clinical TrialsGB Sciences initiates cannabis-based therapy clinical trials consulting services agreement with Worldwide Clinical Trials
seekingalpha.com - July 17 at 9:30 AM
GB Sciences Initiates Cannabis-based Therapy Clinical Trials Consulting Services Agreement with Worldwide Clinical Trials, Inc.GB Sciences Initiates Cannabis-based Therapy Clinical Trials Consulting Services Agreement with Worldwide Clinical Trials, Inc.
finance.yahoo.com - July 17 at 9:30 AM
GB Sciences Inc. Adds Provisional Nevada Recreational Cannabis License for Branded Recreational ProductsGB Sciences Inc. Adds Provisional Nevada Recreational Cannabis License for Branded Recreational Products
finance.yahoo.com - July 10 at 6:53 AM
Cannabis Industry Weekly Recap 7/7/2017Cannabis Industry Weekly Recap 7/7/2017
finance.yahoo.com - July 8 at 10:59 AM
GB Sciences Sells First Cannabis Harvest and Officially Enters Revenue ModeGB Sciences Sells First Cannabis Harvest and Officially Enters Revenue Mode
finance.yahoo.com - July 5 at 7:32 AM
Cannabis, CBD, Vape Products See Uptick in Sales in Thriving Legal Marijuana MarketsCannabis, CBD, Vape Products See Uptick in Sales in Thriving Legal Marijuana Markets
www.prnewswire.com - May 4 at 12:14 PM
Marijuana Stocks: How CEOs Can Navigate Market Volatility (And Survive Spicer And Sessions)Marijuana Stocks: How CEOs Can Navigate Market Volatility (And Survive Spicer And Sessions)
www.benzinga.com - March 10 at 11:30 PM
GROWBLOX SCIENCES, INC. Files SEC form 8-K/A, Entry into a Material Definitive AgreementGROWBLOX SCIENCES, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement
biz.yahoo.com - February 16 at 5:19 PM
GROWBLOX SCIENCES, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal YearGROWBLOX SCIENCES, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
biz.yahoo.com - December 20 at 9:47 PM
Cannabis Stocks Stay Ahead In Exploding Legal Marijuana MarketCannabis Stocks Stay Ahead In Exploding Legal Marijuana Market
www.prnewswire.com - November 29 at 5:07 PM
Cannabis Legalization at the Forefront this WeekCannabis Legalization at the Forefront this Week
www.bizjournals.com - November 9 at 11:07 AM
Pot is on the Ballot in Election 2016, but Investors Should Proceed with CautionPot is on the Ballot in Election 2016, but Investors Should Proceed with Caution
www.thestreet.com - October 27 at 9:50 AM
GROWBLOX SCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersGROWBLOX SCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - October 15 at 9:58 AM
Awareness Continues to Grow for Medical Uses of CannabisAwareness Continues to Grow for Medical Uses of Cannabis
www.prnewswire.com - September 29 at 10:10 AM
GROWBLOX SCIENCES, INC. Files SEC form 8-K, Unregistered Sale of Equity SecuritiesGROWBLOX SCIENCES, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities
biz.yahoo.com - September 9 at 4:59 PM
GROWBLOX SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or PrinciGROWBLOX SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princi
biz.yahoo.com - August 11 at 5:24 PM
GROWBLOX SCIENCES, INC. Files SEC form 10-K, Annual ReportGROWBLOX SCIENCES, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - July 14 at 5:31 PM
GROWBLOX SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive AgreementGROWBLOX SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - June 7 at 5:17 PM

Social Media

Financials

Chart

GB Sciences (OTCMKTS GBLX) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.